Figure 1.

Concentration-response relationship of innovator and generic products of oxacillin in the microbiological assay. A. The slopes and intercepts of OXA-BLA, OXA-COL, OXA-OPH, OXA-PEN, and OXA-SCA were not statistically different from those of OXA-BMS (innovator), thus confirming their pharmaceutical equivalence (P = 0.1165). The standard curves of all products are better described by a single linear regression, shown here with the 95% confidence interval. B. The slopes and intercepts of OXA-CAR, OXA-EXP, OXA-MEM and OXA-VIT were significantly different to the innovator's (P < 0.03458), thus failing pharmaceutical equivalence. As generic products belong to populations different to that of the innovator, each is described by an independent linear regression with their respective coefficient of determination (r²).